Atonco plays an active role in finding new collaborators who are highly experienced in their field of expertise and in establishing partnerships with various actors involved in the field of alphatherapy.
Telix (Melbourne, Australia) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure the manufacturing and GMP supply of the radiopharmaceutical required for the successful completion of Atonco’s clinical studies and commercialization in the United States.
Telix Pharmaceuticals and ATONCO are pleased to announce that the first patient has been treated in the PERTINENCE feasibility study in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
ATONCO AND THE INSTITUT DE CANCÉROLOGIE DE L’OUEST – NANTES ANGERS (ICO) CLINICAL PARTNERS IN THE FIGHT AGAINST CANCER
ATONCO announced today that it has entered into a clinical research partnership agreement with the Institut de Cancérologie de l’Ouest (ICO Nantes Angers) for the clinical study using an alpha emitting radionuclide for the treatment of non-muscle-invasive bladder cancer resistant to standard therapies.
ATONCO ANNOUNCES THE APPOINTMENT OF ADRIEN REYMOND AS DIRECTOR OF REGULATORY AFFAIRS AND QUALITY ASSURANCE
Atonco announced today that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead pharmaceutical, regulatory affairs and quality assurance to be in compliance with Good Clinical Practices (GCP) and preparation for ISO 9001:2015 certification.
Atonco announced today that Sylvain Fanier, Msc. EMBA, will succeed Professor Jean-François Chatal as President.
Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement with France’s ATONCO S.A.S to investigate the use of Molecularly Targeted Radiation (MTR) technology.]